Purpose: Although lapatinib-induced hepatotoxicity can cause severe clinical complications in patients, the factors affecting hepatotoxicity have rarely been investigated. The purpose of this study was to investigate risk factors for hepatotoxicity and time to lapatinib-induced hepatotoxicity.
Methods: This retrospective study was performed on metastatic breast cancer patients treated with lapatinib. Various factors were evaluated for hepatotoxicity and time to hepatotoxicity, including sex, age, body weight, height, body surface area, underlying disease, smoking history, start dose of lapatinib, status of liver metastasis, and concomitant drugs.
Results: Among 159 patients, the percentage of patients with hepatotoxicity after lapatinib initiation was 57.9% (n = 92). Multivariate analysis showed that concomitant use of H2 blockers increased the incidence of hepatotoxicity by 2.3-fold. Patients who received CYP3A4 inducers had 3.1 times higher risk of hepatotoxicity incidence; the attributable risks of H2 blockers and CYP3A4 inducers were 56.7% and 68.1%, respectively. Use of H2 blockers increased the hazard of time to hepatotoxicity by 1.8-fold compared to non-use of H2 blockers.
Conclusions: Our study demonstrated that concomitant use of H2 blockers and CYP3A4 inducers was associated with lapatinib-induced hepatotoxicity. Close liver function monitoring is recommended, especially in patients receiving H2 blockers or CYP3A4 inducers.
Keywords: CYP3A4 inducer; H2 blocker; Hepatotoxicity; Lapatinib.
Risk Factors for Erlotinib-Induced Hepatotoxicity: A Retrospective Follow-Up StudyMK Kim et al. BMC Cancer 18 (1), 988. PMID 30326853.Our study showed that concomitant use of CYP3A4 inducers and H2-antagonist/PPI, liver metastasis, and age ≥ 65 were associated with erlotinib-induced hepatotoxicity. Thus …
Factors Affecting Crizotinib-Induced Hepatotoxicity in Non-Small Cell Lung Cancer PatientsD Jung et al. Med Oncol 35 (12), 154. PMID 30367285.Crizotinib is an orally available tyrosine kinase inhibitor for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer (NSCLC). Despite that crizoti …
Studies on the Role of Metabolic Activation in Tyrosine Kinase Inhibitor-Dependent Hepatotoxicity: Induction of CYP3A4 Enhances the Cytotoxicity of Lapatinib in HepaRG CellsKD Hardy et al. Drug Metab Dispos 42 (1), 162-71. PMID 24191259.Idiosyncratic hepatotoxicity has been associated with the oral tyrosine kinase inhibitor lapatinib, which is used in metastatic breast cancer therapy. Lapatinib is extens …
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Focus on 4-anilinoquinazolinesM Scheffler et al. Clin Pharmacokinet 50 (6), 371-403. PMID 21553932. - ReviewThe 4-anilinoquinazolines (gefitinib, erlotinib and lapatinib) are members of a class of potent and selective inhibitors of the human epidermal growth factor receptor (HE …
Lapatinib Plus Chemotherapy or Endocrine Therapy (CET) Versus CET Alone in the Treatment of HER-2-overexpressing Locally Advanced or Metastatic Breast Cancer: Systematic Review and Meta-AnalysisTE Botrel et al. Core Evid 8, 69-78. PMID 24115917. - ReviewThe combination of CET plus lapatinib increased the overall response rate, progression-free survival, and overall survival in patients with HER-2+ locally advanced or met …